Epithelial-to-mesenchymal transition of the mesothelial cell—its role in the response of the peritoneum to dialysis
1 Servicio de Nefrología, Hospital Universitario La Paz, Madrid, 2 Departamento de Patología, Hospital Universitario de Guadalajara, Guadalajara and 3 Servicio de Nefrología y Unidad de Biología Molecular, Hospital Universitario de la Princesa, Instituto Reina Sof ía de Investigaciones Nefrológicas, Madrid, Spain
Correspondence and offprint requests to: Dr Rafael Selgas, Servicio de Nefrología, Hospital Universitario La Paz, Castellana, 261, Madrid 28046, Spain. Email: rselgas.hlpr{at}salud.madrid.org
Peritoneal membrane fibrosis, ranging from mild inflammation to severe sclerosing peritonitis, is one of the complications of peritoneal dialysis (PD). In parallel with fibrosis, the peritoneum shows a progressive increase of capillaries and vasculopathy, involved in increased small solute transport across the membrane and ultrafiltration failure. Glucose and glucose degradation products from PD solutions are responsible of stimulating transforming growth factor-ß (TGF-ß) and vascular endothelial growth factor (VEGF) production by mesothelial cells (MCs). TGF-ß is a potent pro-fibrotic factor and inducer of epithelial-to-mesenchymal transition (EMT) of the MC. Local production of VEGF by transitional MC appears to play a central role in the processes leading to peritoneal angiogenesis.
This review addresses the mechanism involved in peritoneal structural alteration by dialysis and points to the EMT of MC as the initiating mechanism of peritoneal injury. Information from multiple origins about TGF-ß and VEGF is integrated into EMT process in a comprehensive manner. Regulation and new targets for inhibition of EMT or its deleterious effects are discussed.
Keywords: angiogenesis; epithelial-to-mesenchymal transition; mesothelial cells; peritoneal dialysis; transforming growth factor; vascular endothelial growth factor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L.S. Fan SHOULD WE USE BIOCOMPATIBLE PD SOLUTIONS FOR ALL PATIENTS? Perit. Dial. Int., November 1, 2009; 29(6): 630 - 633. [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Guo, J. J. Carrero, X. Yu, P. Barany, A. R. Qureshi, M. Eriksson, B. Anderstam, M. Chmielewski, O. Heimburger, P. Stenvinkel, et al. Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients Nephrol. Dial. Transplant., June 26, 2009; (2009) gfp315v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A Yu, K.-S. Shin, J. H. Kim, Y.-I. Kim, S. S. Chung, S.-H. Park, Y.-L. Kim, and D.-H. Kang HGF and BMP-7 Ameliorate High Glucose-Induced Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelium J. Am. Soc. Nephrol., March 1, 2009; 20(3): 567 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hirahara, Y. Ishibashi, S. Kaname, E. Kusano, and T. Fujita Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats Nephrol. Dial. Transplant., February 1, 2009; 24(2): 437 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bozkurt, E. Hur, B. Ulkuden, M. Sezak, H. Nar, O. Purclutepe, S. Sen, and S. Duman CAN N-ACETYLCYSTEINE PRESERVE PERITONEAL FUNCTION AND MORPHOLOGY IN ENCAPSULATING PERITONEAL SCLEROSIS? Perit. Dial. Int., February 1, 2009; 29(Supplement_2): S202 - S205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yagi, F. Yotsumoto, and S. Miyamoto Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition Mol. Cancer Ther., October 1, 2008; 7(10): 3441 - 3451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ivanova, M. J. Butt, and D. G. Matsell Mesenchymal transition in kidney collecting duct epithelial cells Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1238 - F1248. [Abstract] [Full Text] [PDF]
|
|